| Autor: |
O'Shea, Evelyn, Daly, Orna, Duggan, Cleona, Crowley, Maeve |
| Předmět: |
|
| Zdroj: |
Clinical & Applied Thrombosis/Hemostasis; Jan-Dec2022, Vol. 28, p1-2, 2p |
| Abstrakt: |
We read with interest Hafeez et al. discussion regarding concern about haemostatic adverse effects post vaccination.[1] Many haemostatic complications post COVID-19 vaccination have been reported including the syndrome of thrombocytopenia and thrombosis, as discussed by Hafeez et al.[1] In 2019, a new pandemic of coronavirus arose from China and quickly spread across the world.[2] It became a public health emergency.[2] Covid-19 infection usually begin with flu like symptoms however, about 10% of the symptomatic subjects may experience more severe course of the disease.[2] Vaccination became the cornerstone strategy in disease control and prevention of new and more severe cases of COVID-19 infection.[2] Here we would like to add to the haemostatic adverse events post vaccination reported by Hafeez et al. and report a case of Acquired Haemophilia A (AHA) one week following a Pfizer-BioNTech SARS-CoV-2 vaccine. COVID-19 infection rates are rising worldwide.[4] Booster doses are being administered and the vaccination programme is being expanded to children.[4] More haemostatic adverse events post vaccination are likely to be seen. The Factor VIII level was reduced [0.01IU/ml [normal range = 0.50 to 1.49 IU/ml]] and Factor VIII inhibitor quantification demonstrated an inhibitor of 70 B.U/ml, consistent with a diagnosis of acquired Haemophilia A. He was treated with one dose [4500 units] of FVIII inhibitor bypassing activity [FEIBA] to control the bleeding and prednisolone 60 mg once daily [reduced dose due to age and history of diabetes]. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
